A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically confirmed superficial transitional cell carcinoma of the bladder pathologically staged as Tis, Ta, or T1. Visible tumors at time of treatment not required. No metastatic disease or muscle invasion.
• •Clinically useful pretreatment bladder function required.
• •No significant prostatic obstructive symptoms associated with impaired or incomplete bladder emptying.
• •No active urinary tract infection.
• •PRIOR/CONCURRENT THERAPY:
• •At least 1 course of prior standard intravesical therapy required.
• •At least 4 weeks since intravesical treatment, with resolution of any local or systemic toxicity.
• •PATIENT CHARACTERISTICS:
• •Age: 18 and over.
• •Performance status: ECOG 0 or 1.
• •Hematopoietic:
• •WBC at least 3,300;
• •Hemoglobin at least 10 g/dL.
• •Hepatic:
• •Bilirubin no greater than 1.5 mg/dL;
• •AST and ALT no greater than 2 times normal.
• •Renal: Creatinine no greater than 1.5 mg/dL.
• •OTHER:
• •Medically able to undergo cystoscopy.
• •No pregnant women.